Bayer Tagged Articles
Anti-clotting drug Eliquis gets FDA approval
Eliquis, a new anti-clotting drug developed by Bristol-Myers Squibb and Pfizer as an alternative to the decades-old warfarin (Coumadin), has finally won approval from the U.S. Food and Drug Administration (FDA).
Bayer expects to reap billions from new blood thinner Xarelto
Bayer is banking on five of its prescription drugs to bring in more than $7 million in annual sales, including its blood thinner Xarelto (rivaroxaban), which is approved for various uses in 120 countries, including the United States. Bayer also
FDA grants new indication for blood thinner Xarelto
The Food and Drug Administration (FDA) has agreed to expand the indication for Bayer and Johnson & Johnson’s new blood thinner Xarelto. The drug can now be used to treat and prevent deep vein thrombosis and pulmonary embolism.
Xarelto makers enjoy huge profits despite bleeding risks
Sales of the blood thinner Xarelto have more than quadrupled compared to prior year quarter to $105 million, and were up $88 million in the second quarter, according to Bayer. Xeralto, a joint effort by Bayer and Johnson & Johnson,
FDA to decide fate of blood thinner Eliquis by March
The Food and Drug Administration (FDA) says it will decide by March 17, 2013, whether to approve Bristol-Myers Squibb Co and Pfizer Inc.’s blood thinner Eliquis for the prevention of strokes in patients with atrial fibrillation. Drug regulators rejected Eliquis
Bayer hopes to expand treatment options for blood thinner Xarelto
Bayer is trying hard to get the Food and Drug Administration (FDA) to agree to expand the treatment options for its new blood thinner Xarelto despite its potential to cause potentially deadly hemorrhaging.
Blood thinner may reduce risk of heart attack in some cardiac patients
Bayer says its blood thinner Xarelto reduces the risk of recurrent heart attacks in patients who have already suffered a severe heart attack. The drug company hopes the findings will help widen the approval for more indications for Xarelto.
FDA rejects blood thinner Eliquis
The Food and Drug Administration (FDA) voted not to approve the new blood thinner Eliquis (apixaban), surprising researchers and analysts alike. Eliquis, made by Squibb and Pfizer, was designed to go head-to-head with warfarin, an anticoagulant used to prevent strokes
FDA rejects Xarelto’s bid to treat acute coronary syndrome
The Food and Drug Administration (FDA) rejected expanding the indication for the new blood thinner Xarelto to prevent heart attacks and strokes in patients with a common heart condition known as acute coronary syndrome. The agency said there was too